Scyllo-inositol: Phase II data
Top-line data from the modified intent-to-treat (mITT) population (n=166) of the dose-ranging, double-blind, North American Phase II AD201 trial showed that twice-daily 250 mg ELND005 for up to 18 months missed the co-primary endpoints of significantly improving cognitive and functional measures as determined by the NTB and ADCS-ADL scales, respectively, vs. placebo. However, the partners said that ELND005 demonstrated a biological effect on beta amyloid in cerebrospinal fluid (CSF) in a subgroup of patients who provided CSF samples (n=20), as well as "some effects on clinical endpoints" in an exploratory analysis of the trial. As a result, the partners said they plan to advance ELND005 into Phase III development, but would not disclose any further details. ...